Product Title: Biologics in Otolaryngology, An Issue of Otolaryngologic Clinics of North America (Volume 54-4) (The Clinics: Surgery, Volume 54-4) (Original PDF from Publisher)
Format:
Publisher PDF, File Size = 7.90 MB
Overview (Details, Topics and Speakers):
By Sarah K. Wise MD MSCR, Ashkan Monfared MD, Nicole Schmitt MD
This issue of Otolaryngologic Clinics, guest edited by Drs. Sarah K. Wise, Ashkan Monfared, and Nicole C. Schmitt is devoted to Biologics in Otolaryngology. This issue is one of six selected each year by our series consulting editor, Dr. Sujana S. Chandrasekhar. Articles in this issue include: Biologics in otolaryngology overview, Current evidence for biologic therapy in chronic rhinosinusitis with nasal polyposis, Choosing the right patient for biologic therapy in CRSwNP, Knowledge gaps and research needs for biologic therapy in rhinology practice, Mechanisms and practical use of biologic therapies for allergy and asthma indications, Immunotherapeutic strategies in head and neck cancer, Cetuximab in head and neck cancer, Anti-PD-1 immune checkpoint blockade for head and neck cancer, Advances in adoptive cell therapy for head and neck cancer, Biologics for the treatment of recurrent respiratory papillomatosis, Past and future biologics for otologic disorders, Biological treatments for Neurofibromatosis Type II and other skullbase disorders, and Biologics in treatment of autoimmune ear disorders.
Product Details
- Publisher : Elsevier (July 29, 2021)
- Language : English
- Hardcover : 240 pages
- ISBN-10 : 0323835368
- ISBN-13 : 978-0323835367
- ISBN-13 : 9780323835367
- eText ISBN: 9780323835374
Delivery Method
the Biologics in Otolaryngology, An Issue of Otolaryngologic Clinics of North America (Volume 54-4) (The Clinics: Surgery, Volume 54-4) (Original PDF from Publisher) course/book will be provided for customer as download link. download link has NO Expiry and can be used anytime.
Contact Us
contact us to our email at [email protected] or fill in the form below:
Reviews
There are no reviews yet.